title: p16(INK4a) promoter methylation and protein expression in breast fibroadenoma and carcinoma.
abstract: The potential role of p16(INK4a) methylation in breast cancer is controversial whereas there are no data on fibroadenoma. To assess if inactivation of p16(INK4a) by promoter hypermethylation occurs in this hyperproliferative benign breast lesion or, on the contrary, it is strictly related to the carcinogenic process, we have tested the different histological components of 15 cases of fibroadenoma and the intraductal and infiltrating components of 15 cases of carcinoma and their adjacent non-tumoral epithelium. All samples were obtained by laser-assisted microdissection. The relationship between promoter methylation status, immunohistochemical protein expression and ki67 proliferative activity was evaluated for each lesion. Our data demonstrate that hypermethylation of p16(INK4a) promoter is a common event occurring at similar frequency in all the different histological areas of the benign and malignant breast lesions taken into exam. Conversely, protein p16 expression, although heterogeneously distributed within the section, is considerably higher in breast carcinoma as compared to fibroadenoma in both tumoral and non-tumoral epithelia and stroma. The protein localization was almost exclusively nuclear in fibroadenoma and non-tumoral epithelia whereas, in carcinoma, the staining was both nuclear and cytoplasmic or cytoplasmic alone. Furthermore, in a subset of fibroadenoma with higher proliferative activity, p16 protein expression was substantially decreased as compared to those showing lower proliferation. We did not observe this association in carcinomas. Our data demonstrate that the hypermethylation of the p16(INK4a) promoter is not specifically associated with malignancy and that, on the contrary, the overexpression of p16 and its cytoplasmic sequestration is a feature of breast carcinoma.
authors.affiliation: Laboratory of Tumor Genetics, Istituto Nazionale per la Ricerca sul Cancro (IST), Genova, Italy.
authors.forename: Angela
authors.initials: A
authors.lastname: Di Vinci
authors.forename: Luisa
authors.initials: L
authors.lastname: Perdelli
authors.forename: Barbara
authors.initials: B
authors.lastname: Banelli
authors.forename: Sandra
authors.initials: S
authors.lastname: Salvi
authors.forename: Ida
authors.initials: I
authors.lastname: Casciano
authors.forename: Ilaria
authors.initials: I
authors.lastname: Gelvi
authors.forename: Giorgio
authors.initials: G
authors.lastname: Allemanni
authors.forename: Edoardo
authors.initials: E
authors.lastname: Margallo
authors.forename: Beatrice
authors.initials: B
authors.lastname: Gatteschi
authors.forename: Massimo
authors.initials: M
authors.lastname: Romani
mesh_terms: D001943:Breast Neoplasms / Q000235:genetics* / Q000473:pathology*; D002277:Carcinoma / Q000235:genetics* / Q000473:pathology*; D019941:Cyclin-Dependent Kinase Inhibitor p16 / Q000096:biosynthesis / Q000235:genetics* / Q000378:metabolism*; D003593:Cytoplasm / Q000737:chemistry; D019175:DNA Methylation; D005260:Female; D018226:Fibroadenoma / Q000235:genetics* / Q000473:pathology*; D020869:Gene Expression Profiling; D006801:Humans; D007150:Immunohistochemistry; D019394:Ki-67 Antigen / Q000032:analysis; D011401:Promoter Regions, Genetic; D014407:Tumor Cells, Cultured
chemical_list: D019941:Cyclin-Dependent Kinase Inhibitor p16; D019394:Ki-67 Antigen